The news is directly about Alnylam Pharmaceuticals and is likely to influence investor sentiment. The lowering of the price target might be seen as a negative signal, but the maintenance of the 'Outperform' rating suggests that RBC Capital still sees potential in the stock. The impact on the stock price in the short term is uncertain, hence the neutral score.